Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Case Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT00498979
First received: July 10, 2007
Last updated: January 11, 2012
Last verified: January 2012

July 10, 2007
January 11, 2012
May 2007
May 2010   (final data collection date for primary outcome measure)
Safety of the combination of sodium stibogluconate and interferon alfa-2b with chemotherapy [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
  • Safety of the combination of sodium stibogluconate and interferon alfa-2b with chemotherapy
  • Activity of sodium stibogluconate in augmenting cytokine effects
Complete list of historical versions of study NCT00498979 on ClinicalTrials.gov Archive Site
  • Effects of sodium stibogluconate on interferon alfa-2b induced gene modulation and signal transduction pathways by measuring the serum soluble gene product [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Effectiveness of sodium stibogluconate in inhibiting the protein tyrosine phosphatases SHP-1 and SHP-2 assayed from peripheral blood leukocytes [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Pharmacokinetics of sodium stibogluconate in serum at escalating doses [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Clinical response to the combination of sodium stibogluconate and interferon alfa-2b as priming for combination chemotherapy [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Effects of sodium stibogluconate on interferon alfa-2b induced gene modulation and signal transduction pathways by measuring the serum soluble gene product
  • Effectiveness of sodium stibogluconate in inhibiting the protein tyrosine phosphatases SHP-1 and SHP-2 assayed from peripheral blood leukocytes
  • Pharmacokinetics of sodium stibogluconate in serum at escalating doses
  • Clinical response to the combination of sodium stibogluconate and interferon alfa-2b as priming for combination chemotherapy
Not Provided
Not Provided
 
Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers
Phase I Evaluation of Sodium Stibogluconate in Combination With Interferon α-2b Followed by Cisplatin, Vinblastine and Dacarbazine for Patients With Melanoma or Malignancies Potentially Responsive to SSG and/or Interferons

RATIONALE: Sodium stibogluconate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Interferon alfa-2b may interfere with the growth of tumor cells and slow the growth of melanoma and other cancers. Drugs used in chemotherapy, such as cisplatin, vinblastine, and dacarbazine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving sodium stibogluconate and interferon alfa-2b together with combination chemotherapy may kill more tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of sodium stibogluconate when given together with interferon alfa-2b, cisplatin, vinblastine, and dacarbazine in treating patients with advanced melanoma or other cancer.

OBJECTIVES:

Primary

  • To determine the safety of the combination of sodium stibogluconate and interferon alfa-2b with chemotherapy.
  • To confirm the activity of sodium stibogluconate in augmenting cytokine effects.

Secondary

  • To quantify the effects of sodium stibogluconate on interferon alfa-2b induced gene modulation and signal transduction pathways by measuring the serum soluble gene products.
  • To define the effectiveness of sodium stibogluconate in inhibiting the protein tyrosine phosphatases SHP-1 and SHP-2 assayed from peripheral blood leukocytes of patients receiving sodium stibogluconate in combination with interferon alfa-2b.
  • To define the pharmacokinetics of sodium stibogluconate in serum at escalating doses.
  • To assess clinical response to the combination of sodium stibogluconate and interferon alfa-2b as priming for combination chemotherapy.

OUTLINE:

  • Course 1: Patients receive sodium stibogluconate IV over 15 minutes on day 1 and days 15-18; interferon alfa-2b subcutaneously (SC) on days 8-12 and 15-18; cisplatin IV over 30-60 minutes and vinblastine IV on days 19 and 20; and dacarbazine. After a 2-week rest period, patients proceed to course 2.
  • Course 2 and all subsequent courses: Patients receive sodium stibogluconate IV over 15 minutes and interferon alfa-2b SC on days 1-4; cisplatin IV over 30-60 minutes and vinblastine IV on days 5 and 6; dacarbazine. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.* NOTE: *Patients with stage IV disease who have no evidence of disease [NED} receive only 4 courses of therapy.

Cohorts of 6 patients receive escalating doses of sodium stibogluconate until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which dose-limiting toxicity occurs (i.e., no more than 1 patient at a given dose experiences DLT).

Patients undergo blood sample collection periodically for immunological and pharmacokinetic studies. Samples are analyzed for serum soluble gene products and protein tyrosine phosphatase inhibition.

Interventional
Phase 1
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Stage IV Melanoma
  • Biological: recombinant interferon alfa-2b
    recombinant interferon alfa-2b
    Other Name: IFN 2b
  • Drug: cisplatin
    recombinant interferon alfa-2b
    Other Name: CDDP
  • Drug: sodium stibogluconate
    sodium stibogluconate
    Other Name: sodium stibogluconate
  • Drug: dacarbazine
    dacarbazine
    Other Name: DTIC
  • Drug: vinblastine
    vinblastine
    Other Name: VBL
Experimental: recombinant interferon alfa-2b
recombinant interferon alfa-2b
Interventions:
  • Biological: recombinant interferon alfa-2b
  • Drug: cisplatin
  • Drug: sodium stibogluconate
  • Drug: dacarbazine
  • Drug: vinblastine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
22
January 2012
May 2010   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Histologically confirmed melanoma or other malignancies

    • Must be refractory or resistant to established treatments OR have metastatic disease for which no effective therapy has been established
    • Gliomas or controlled CNS metastasis allowed

      • A CT scan or MRI must confirm stable brain metastases within 28 days of study entry
      • Patients with primary CNS malignancies refractory to other therapies are eligible
  • Malignancy potentially responsive to sodium stibogluconate and/or interferon alfa-2b and combination chemotherapy
  • Patients must have measurable or evaluable disease

    • Evaluable disease can include clinically or radiographically nonmeasurable tumor, specific tumor markers, or stage IV patients with no evidence of disease (NED)

PATIENT CHARACTERISTICS:

  • Inclusion criteria:

    • ECOG performance status 0-2
    • Granulocytes > 1,500/μl
    • Platelets > 100,000/μl
    • Creatinine < 1.5 x upper limit of normal (ULN)
    • Bilirubin < 1.5 x ULN
    • AST and ALT < 1.5 x ULN (unless due to hepatic metastases)
    • Potassium ≤ 5.0 mmol/L
    • Magnesium ≤ 2.4 mg/dL
    • Creatinine clearance ≥ 60 cc/min
    • Ejection fraction ≥ 50%
  • Exclusion criteria:

    • Pregnant or lactating women and fertile women or men unless surgically sterile or using effective contraception

      • All female patients of childbearing potential or less than 1 year postmenopausal must have a negative β-HCG pregnancy test at baseline and practice a medically acceptable method of birth control (i.e., oral contraceptives for at least 3 months, implantation of an intrauterine device for at least 2 months, or barrier methods [e.g., vaginal diaphragm, vaginal sponge, or condom with spermicidal jelly]) during and for 3 months after study initiation
    • History of atrial fibrillation, flutter, or other serious arrhythmia (excluding asymptomatic atrial or ventricular premature complexes) in the past 24 months
    • History of congestive heart failure currently requiring treatment; angina pectoris; or other severe cardiovascular disease (i.e., New York Heart Association class III or IV heart disease)
    • Baseline ECG abnormalities suggestive of cardiac conduction delay (i.e., first degree or greater atrio-ventricular block and/or complete or incomplete [QRS > 120 ms] bundle branch block)
    • Baseline ECG abnormalities suggestive of repolarization abnormalities (i.e., QTc ≥ 0.48 sec)
    • Culture positive acute infections requiring antibiotics within the past 14 days

      • Patients on long term suppressive antibiotic therapies are eligible
    • Known to be positive for HBsAg
    • Patients judged to not be psychologically prepared to understand informed consent or comply with an investigational study

PRIOR CONCURRENT THERAPY:

  • Inclusion criteria:

    • Prior interferon therapy is allowed if administered ≥ 4 months ago
    • At least 3 weeks since prior major surgery, radiation therapy, or chemotherapy
  • Exclusion criteria:

    • No prior treatment with interferon, sodium stibogluconate, cisplatin, vinblastine, or dacarbazine, except if given in an adjuvant setting
    • Patients with a prior history of solid organ allografts or allogeneic bone marrow transplant
    • Patients taking the following medications will not be eligible:

      • Amiodarone (Cordarone)
      • Disopyramide (Norpace)
      • Dofetilide (Tikosyn)
      • Procainamide (Procanbid or Pronestyl)
      • Quinidine (Quinaglute)
      • Sotalol (Betapace)
      • Erythromycin
      • Azithromycin (Z-pack)
      • Clarithromycin (Biaxin)
      • Pentamidine (Pentacarinat)
      • Trimethoprim-sulfamethoxazole (Bactrim)
      • Bepridil (Vascor)
      • Phenothiazines (e.g., prochlorperazine [Compazine], promethazine [Phenergan], or chlorpromazine [Thorazine])
      • Butyrophenones (e.g., Haloperidol [Haldol])
      • Risperidone (Risperdal)
      • Any other antipsychotic medication
      • Tricyclic or tetracyclic antidepressants (e.g., imipramine [Tofranil], amitriptyline [Elavil], desipramine [Norpramin], or nortriptyline [Pamelor])
      • Monoamine oxidase inhibitors
      • High-dose methadone
      • Arsenic trioxide
      • Dolasetron (Anzemet)
      • Any herbal preparations
    • Use of daily glucocorticoids except for physiological replacement
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00498979
CASE3Y06, P30CA043703
Yes
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
National Cancer Institute (NCI)
Principal Investigator: Ernest C. Borden, MD Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
January 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP